Susan Johnson, founder and CEO of Medfield Pharmaceuticals, with conflicting recommendations for the extension of patent life of the company’s flagship product, Fleximat, planned to go patent faced in two years. With only three other products in Medfield lineup of drugs, one of which has just the U.S. Food and Drug Administration has received approval, is strategic management of the company’s product pipeline is of utmost importance. But a recent $ 750 million offer to buy the com … Read more »

Susan Johnson, founder and CEO of Medfield Pharmaceuticals, with conflicting recommendations for the extension of patent life of the company’s flagship product, Fleximat, planned to go patent faced in two years. With only three other products in Medfield lineup of drugs, one of which has just the U.S. Food and Drug Administration has received approval, is strategic management of the company’s product pipeline is of utmost importance. But a recent $ 750 million offer to buy the company has completely shifted their focus. With this offer, Johnson has the opportunity to finish the business on a high note. Before the recommendation, Johnson has to determine the value of the company, with a careful review of their existing and potential future products. But this is more than just a financial decision because Johnson and Medfield employees believe in general that the company is engaged in critically important work. This case is intended audience for Bachelor, MBA, Executive Education and MBA exec. It is taught as a core course, “Financial Management and Policy” at the Darden Graduate School of Business Administration.
«Hide

from
Marc Lipson,
Jenny Mead,
Jared Harris
Source: Darden School of Business
13 pages.
Release Date: 14 November 2011. Prod #: UV5632-PDF-ENG
Medfield Pharmaceuticals HBR case solution

[related_post themes="flat"]